A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV

被引：4

作者：

Cheng, Shu-Hsing ^{[1
,2
]}

Lien, Chia En ^{[3
,4
]}

Hsieh, Szu-Min ^{[5
,6
]}

Cheng, Chien-Yu ^{[1
,4
]}

Liu, Wang-Da ^{[5
,7
]}

Lo, Ching-Lung ^{[8
,9
]}

Ko, Wen-Chien ^{[8
,9
]}

Chen, Yen-Hsu ^{[10
,11
,12
]}

Huang, Ching-Tai ^{[13
,14
]}

Chang, Hsiao-Ting ^{[15
,16
]}

Hwang, Shinn-Jang ^{[15
,16
]}

Wang, Ning-Chi ^{[17
]}

Liu, Ming-Che ^{[18
,19
]}

Lee, Yu-Lin ^{[20
,21
]}

Tai, I-Chen ^{[3
]}

Estrada, Josue Antonio Garcia ^{[3
]}

Lin, Tzou-Yien ^{[14
,22
]}

Lee, Wen-Sen ^{[23
,24
]}

机构：

[1] Taoyuan Gen Hosp, Dept Infect Dis, Minist Hlth & Welf, Taoyuan 330, Taiwan

[2] Taipei Med Univ, Sch Publ Hlth, Taipei 110, Taiwan

[3] Medigen Vaccine Biol, Taipei 114, Taiwan

[4] Natl Yang Ming Chiao Tung Univ, Inst Publ Hlth, Coll Med, Taipei 112, Taiwan

[5] Natl Taiwan Univ Hosp, Dept Internal Med, Div Infect Dis, Taipei 100, Taiwan

[6] Natl Taiwan Univ, Coll Med, Taipei 106, Taiwan

[7] Natl Taiwan Univ, Dept Med, Canc Ctr, Taipei 100, Taiwan

[8] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan 704, Taiwan

[9] Natl Cheng Kung Univ, Coll Med, Dept Med, Tainan 701, Taiwan

[10] Kaohsiung Med Univ Hosp, Dept Internal Med, Div Infect Dis, Kaohsiung 807, Taiwan

[11] Kaohsiung Med Univ, Grad Inst Med, Sepsis Res Ctr, Sch Med, Kaohsiung 807, Taiwan

[12] Kaohsiung Med Univ, Ctr Trop Med & Infect Dis, Kaohsiung 807, Taiwan

[13] Chang Gung Mem Hosp, Dept Infect Dis, Taoyuan 333, Taiwan

[14] Chang Gung Univ, Coll Med, Taoyuan 333, Taiwan

[15] Taipei Vet Gen Hosp, Dept Family Med, Taipei 112, Taiwan

[16] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei 112, Taiwan

[17] Triserv Gen Hosp, Taipei 114, Taiwan

[18] Taipei Med Univ Hosp, Clin Res Ctr, Taipei 110, Taiwan

[19] Taipei Med Univ, Coll Oral Med, Sch Dent Technol, Taipei 110, Taiwan

[20] Changhua Christian Hosp, Dept Internal Med, Changhua 500, Taiwan

[21] Natl Chung Hsing Univ, Program Med Biotechnol, Taichung 402, Taiwan

[22] Chang Gung Mem Hosp, Dept Paediat, Taoyuan 333, Taiwan

[23] Taipei Med Univ, Wan Fang Hosp, Dept Internal Med, Div Infect Dis, Taipei 116, Taiwan

[24] Taipei Med Univ, Coll Med, Sch Med, Dept Internal Med, Taipei 110, Taiwan

来源：

VACCINES | 2023年 / 11卷 / 01期

关键词：

COVID-19; vaccine; CpG; 1018; S-2P protein; HIV; CD4; CD8; ratio; immunogenicity; HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-B VACCINATION; T-CELL DIFFERENTIATION; ANTIBODY-RESPONSE; COVID-19; VACCINE; MESSENGER-RNA; SARS-COV-2; INFECTION; NUMBER; ADULTS;

D O I：

10.3390/vaccines11010018

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background: This study aimed to assess the safety and immunogenicity of MVC-COV1901, a recombinant COVID-19 protein vaccine, containing S-2P protein adjuvanted with CpG 1018 and aluminum hydroxide, for people living with HIV (PWH). Methods: A total of 57 PWH of >= 20 years of age who are on stable antiretroviral therapy were compared with 882 HIV-negative participants. Participants received two doses of MVC-COV1901 28 days apart. Results: No vaccine-related serious adverse events (SAEs) were recorded. Seroconversion rates (SCRs) of 100% and 99.8% were achieved in PWH and comparators, respectively, 28 days after the second dose. After adjusting for sex, age, BMI category, and comorbidity, the adjusted GMT ratio of comparator/PWH was 3.2 (95% CI 2.5-4). A higher CD4/CD8 ratio was associated with a higher GMT (R = 0.27, p = 0.039). MVC-COV1901 has shown robust safety but elicited weaker immune responses in PWH. Conclusions: Further investigations may be needed to determine whether PWH require distinct immunization strategies with improved immunogenicity. The main study is registered at ClinicalTrials.gov (NCT04695652).

引用

页数：14

共 50 条

[31] Immunogenicity, effectiveness, and safety of SARS-CoV-2 vaccination in people with HIV
Griffin, David W. J.
Pai Mangalore, Rekha
Hoy, Jennifer F.
McMahon, James H.
AIDS, 2023, 37 (09) : 1345 - 1360
[32] A report of stable segmental vitiligo with exacerbations following Oxford-AstraZeneca and MVC-COV1901 COVID-19 vaccinations
Tsai, Tsung-Fu
Ng, Chau
DERMATOLOGICA SINICA, 2022, 40 (04) : 255 - 256
[33] Infertility-therapies/mvc-cov1901/sodium-chlorideThrombosis, pulmonary congestion and bilateral pleural effusion: case report
Reactions Weekly, 2023, 1946 (1) : 292 - 292
[34] The propositive study: Immunogenicity and safety of a four-component recombinant protein-based vaccine against MenB and a quadrivalent conjugate MenACWY vaccine in people living with HIV
Isitt, Catherine
Bartolf, Angela
Andrews, Nick
Athaide, Shehnaz
Pryce-Williams, Richard
Townsend-Payne, Kelly
Borrow, Ray
Ladhani, Shamez
Heath, Paul T. T.
Cosgrove, Catherine A. A.
HIV MEDICINE, 2023, 24 (09) : 979 - 989
[35] Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan
Hsieh, Szu-Min
Liu, Ming-Che
Chen, Yen-Hsu
Lee, Wen-Sen
Hwang, Shinn-Jang
Cheng, Shu-Hsing
Ko, Wen-Chien
Hwang, Kao-Pin
Wang, Ning-Chi
Lee, Yu-Lin
Lin, Yi-Ling
Shih, Shin-Ru
Huang, Chung-Guei
Liao, Chun-Che
Liang, Jian-Jong
Chang, Chih-Shin
Chen, Charles
Lien, Chia En
Tai, I-Chen
Lin, Tzou-Yien
LANCET RESPIRATORY MEDICINE, 2021, 9 (12): : 1396 - 1406
[36] Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV
Vergori, Alessandra
Lepri, Alessandro Cozzi
Cicalini, Stefania
Matusali, Giulia
Bordoni, Veronica
Lanini, Simone
Meschi, Silvia
Iannazzo, Roberta
Mazzotta, Valentina
Colavita, Francesca
Mastrorosa, Ilaria
Cimini, Eleonora
Mariotti, Davide
De Pascale, Lydia
Marani, Alessandra
Galli, Paola
Garbuglia, AnnaRosa
Castilletti, Concetta
Puro, Vincenzo
Agrati, Chiara
Girardi, Enrico
Vaia, Francesco
Antinori, Andrea
NATURE COMMUNICATIONS, 2022, 13 (01)
[37] Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV
Alessandra Vergori
Alessandro Cozzi Lepri
Stefania Cicalini
Giulia Matusali
Veronica Bordoni
Simone Lanini
Silvia Meschi
Roberta Iannazzo
Valentina Mazzotta
Francesca Colavita
Ilaria Mastrorosa
Eleonora Cimini
Davide Mariotti
Lydia De Pascale
Alessandra Marani
Paola Gallì
AnnaRosa Garbuglia
Concetta Castilletti
Vincenzo Puro
Chiara Agrati
Enrico Girardi
Francesco Vaia
Andrea Antinori
Nature Communications, 13
[38] Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants
Chiu, Chun-Hsiang
Chang, Yu-Hsiu
Tao, Chi-Wei
Chang, Feng-Yee
Chiu, Kuo-Chou
Chang, Tien-Wei
Yen, Li-Chen
MICROBIOLOGY SPECTRUM, 2022, 10 (05):
[39] Immunogenicity of an Inactivated COVID-19 Vaccine in People Living with HIV in Guangxi, China: A Prospective Cohort Study
Wu, Yuting
Wang, Xinwei
Huang, Yunxuan
Chen, Rongfeng
Xu, Yuexiang
Wei, Wudi
Qin, Fengxiang
Yuan, Zongxiang
Su, Jinming
Chen, Xiu
Liu, Jie
Wen, Liufang
Shi, Minjuan
Qin, Tongxue
Liao, Yinlu
Lu, Beibei
Tao, Xing
Wang, Cuixiao
Chen, Shanshan
Li, Jinmiao
Liu, William J.
Ye, Li
Liang, Hao
Jiang, Junjun
VIRUSES-BASEL, 2024, 16 (09):
[40] Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial
Estephan, Lila
Lin, Ying-Chin
Lin, Yi-Tsung
Chen, Yen -Hsu
Pan, Sung-Ching
Hsieh, Szu-Min
Torkehagen, Paal Fure
Weng, Yi-Jen
Cheng, Hao-Yuan
Estrada, Josue Antonio
Waits, Alexander
Chen, Charles
Lien, Chia En
VACCINE, 2023, 41 (23) : 3497 - 3505

← 1 2 3 4 5 →